The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental New Drug Application to FDA seeking approval of a new indication for Erleada (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe